Data from two KEYNOTE trials show pembrolizumab benefited patients with advanced SCLC
ATLANTA -- The anti-PD-1 monoclonal antibody pembrolizumab (Keytruda) showed promising antitumor activity with durable responses in patients with pretreated, advanced ...